Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04440774
Other study ID # CHIKA01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 23, 2020
Est. completion date February 18, 2022

Study information

Verified date September 2021
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase Ib, single centre, double-blind, double-dummy placebo-controlled, randomised, stepwise dose escalated, vaccine trial to assess the safety and immunogenicity of the candidate ChAdOx1 Chik and ChAdOx1 Zika vaccines, given as a standalone vaccines or in co-administration. Healthy volunteers aged 18-50 years old, residents of the metropolitan area of Monterrey (Mexico), will be recruited as participants


Description:

This trial consists of 4 intervention arms according to the vaccination product: 1) ChAdOx1 Chik, 2) ChAdOx1 Zika, 3) ChAdOx1 Chik and ChAdOx1 Zika as contralateral co-administration, and 4) placebo. There will be a total of 120 participants divided in ten study groups with 12 participants per group (Table 5.1). Groups 1 to 3 will receive ChAdOx1 Chik + placebo administered contralaterally, Groups 4 to 6 will receive ChAdOx1 Zika + placebo administered contralaterally, and Groups 7 to 9 will receive both ChAdOx1 Chik and ChAdOx1 Zika administered contralaterally. Group 10 will receive placebo in both arms. Enrolment into this study will be implemented in a step-wise dose escalation manner. Participants will be first recruited into the vaccination groups at the lowest dose (Groups 1, 4 and 7). It is only after completion of these low dose groups and upon satisfactory interim clinical safety reviews that participants will be enrolled into the mid dose groups (Groups 2, 5 and 8). Participants in the high dose groups (Groups 3, 6 and 9) will be enrolled last, after completion and interim clinical safety reviews from the mid dose groups. Participants allocated to the Placebo group (Group 10) will be evenly distributed across the dose escalation model. Randomisation procedures will be implemented accordingly, at a ratio of 3:3:3:1 for each of the four intervention arms. The study involves a total of 9 visits (screening inclusive) and follow up will be undertaken for 6 months after vaccination day Innovate UK (project number 971557)


Recruitment information / eligibility

Status Completed
Enrollment 120
Est. completion date February 18, 2022
Est. primary completion date February 18, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria: 1. Healthy men aged 18 to 50 (inclusive) years at the time of screening. 2. Healthy women aged 18 to 50 (inclusive) of child-bearing potential who agree to practice continuous effective contraception (see below) during the study and test negative for pregnancy on the day(s) of screening and vaccination. 3. Are residents of the metropolitan area of Monterrey, Nuevo León. 4. Provide written informed consent for participation in the study. 5. Able and willing (in the Investigator's opinion) to comply with all study requirements. 6. Agreement to inform study team of any impending vaccinations either before or during participation in the study. 7. Agreement to refrain from blood donation during the course of the study. 8. Agreement to refrain from receipt of any alphavirus or flavivirus vaccine throughout the duration of the study (e.g. investigational or licensed Yellow Fever, Japanese Encephalitis, Tick Borne Encephalitis or Dengue virus vaccines). Exclusion Criteria: 1. Participation in another clinical trial in the 30 days preceding enrolment or during the study period. 2. Prior receipt of an investigational or licensed vaccine likely to impact on interpretation of the trial data (e.g. Adenovirus vectored vaccine, Chikungunya virus vaccine, Zika virus vaccine, Dengue virus vaccine). 3. Prior receipt of any vaccines administered =30 days before enrolment and/or planned during the during the study. 4. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate. 5. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed). 6. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Any history of anaphylaxis in relation to vaccination. 7. History of autoimmune disease. 8. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema. 9. Pregnancy, lactation or willingness/intention to become pregnant during the study. 10. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ). 11. History of serious psychiatric condition likely to affect participation in the study 12. Bleeding disorder (eg. factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture. 13. Any other serious chronic illness requiring hospital specialist supervision at present or during the last 6 months. 14. Suspected or known current alcohol abuse. For men, intake greater than 5 drinks on a single occasion or more than 15 drinks per week; and for women, more than 4 drinks on a single occasion or more than 8 drinks per week. One drink =14 grams of pure alcohol. 15. Suspected or known injecting drug abuse in the 5 years preceding enrolment. 16. Seropositive for hepatitis B surface antigen (HBsAg). 17. Seropositive for hepatitis C virus (antibodies to HCV). 18. Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis. 19. Has history of chronic or acute severe neurologic condition. Including: Neurologic and Neuroinflammatory Disorders: ADEM, including site specific variants, Cranial Nerve Disorders (including paralyses/paresis), GBS (including Miller Fisher Syndrome and other variants), Immune-mediated Peripheral Neuropathies and Plexopathies, Optic Neuritis, Multiple Sclerosis, Narcolepsy, Transverse Myelitis, meningitis, or meningoencephalitis. 20. Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data. 21. Seropositivity or cross-reactivity to Chikungunya virus, Zika virus or Dengue virus on screening tests.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
CHIK low dose
A single dose of 5x10^9 vp ChAdOx1 Chik
CHIK mid dose
A single dose of 2.5x10^10 vp ChAdOx1 Chik
CHIK high dose
A single dose of 5x10^10 vp ChAdOx1 Chik
ZIKA low dose
A single dose of 5x10^9 vp ChAdOx1 Zika
ZIKA mid dose
A single dose of 2.5x10^10 vp ChAdOx1 Zika
ZIKA high dose
A single dose of 5x10^10 vp ChAdOx1 Zika
Saline placebo
A single dose of isotonic saline solution (0.9%)

Locations

Country Name City State
Mexico Hospital Universitario "Dr. José Eleuterio González" de la Universidad Autónoma de Nuevo León. Monterrey Nuevo León

Sponsors (1)

Lead Sponsor Collaborator
University of Oxford

Country where clinical trial is conducted

Mexico, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of local reactogenicity signs and symptoms Occurrence of solicited local reactogenicity signs and symptoms for 7 days following vaccination. 7 days post vaccination
Primary Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of solicited systemic reactogenicity signs and symptoms Occurrence of solicited systemic reactogenicity signs and symptoms for 7 days following the vaccination. 7 days post vaccination
Primary Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of unsolicited adverse events Occurrence of unsolicited adverse events for 28 days following vaccination 28 days post vaccination
Primary Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants through standard blood tests (full blood count, liver and kidney function tests) Change from baseline for safety laboratory measures (haematology and biochemistry blood results) 28 days post vaccination
Primary Assess the safety profile and tolerability of ChAdOx1 Chik and ChAdOx1 Zika in healthy participants: occurrence of serious adverse events during the whole study duration Occurrence of serious adverse events during the whole study duration 6 months post vaccination
Secondary Assess the humoral immunogenicity of the candidate vaccines ChAdOx1 Chik and ChAdOx1 Zika via PRNT50 Plaque-reduction neutralisation tests at 50% (PRNT50) against chikungunya and Zika virus. 6 months post vaccination
Secondary Assess the humoral immunogenicity of the candidate vaccines ChAdOx1 Chik and ChAdOx1 Zika via IgG ELISA antibody titres IgG ELISA antibody titres against proteins of Chikungunya and Zika virus 6 months post vaccination
See also
  Status Clinical Trial Phase
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT05153018 - Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu N/A
Active, not recruiting NCT04343521 - Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases Phase 3
Completed NCT03992872 - Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) Phase 2
Completed NCT03382964 - Study to Assess the Safety and Immunogenicity of a Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Phase 1
Completed NCT02831699 - The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico
Recruiting NCT01099852 - Cohort of Patients Infected by an Arbovirus
Completed NCT06257810 - Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and Antibiotic Use in West Africa Phase 4
Suspended NCT05218304 - Baromètre Santé Adulte 2021-2022 N/A
Recruiting NCT04615364 - Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
Completed NCT04650399 - A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents Phase 3
Not yet recruiting NCT04672577 - Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Follow up on Long-term Sequelae of Arboviral Infections and Malaria
Completed NCT04434846 - Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
Recruiting NCT04838574 - Post-Chikungunya Rheumatism - Rheumatology Follow-up of Patients After 15 Years
Recruiting NCT04619823 - Virological and Immunological Determinants of Arbovirus Infection in New Caledonia N/A
Completed NCT03101111 - Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area Phase 2
Completed NCT02463968 - Chikungunya Arthritis in the Americas N/A
Active, not recruiting NCT04566484 - Seamless Controlled Trial To Evaluate Safety And Immunogenicity of Chikungunya Vaccine in LatinAmerica and Asia Phase 2/Phase 3
Completed NCT04603131 - Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine Phase 1